SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase of Trial: Phase I/II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs SL 401 (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Stemline Therapeutics
- 06 Jul 2017 Planned number of patients changed from 60 to 120.
- 06 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History